Host cell entry and neutralisation sensitivity of the SARS-CoV-2 XBB.1.16 lineage

查看全文 作　　者：Inga [1]Nehlmeier;Amy [1,2]Kempf;Prerna [1,2]Arora;Anne [3]Cossmann;Alexandra Dopfer-[3,4]Jablonka;Metodi [3]V.Stankov;Sebastian [5]R.Schulz;Hans-Martin [5]Jäck;Georg [3,4,6]M.N.Behrens;Stefan [1,2]Pöhlmann;Markus [1,2]Hoffmann 机构地区：[1]Infection Biology Unit,German Primate Center—Leibniz Institute for Primate Research,Kellnerweg 4,37077,Göttingen,Germany;[2]Faculty of Biology and Psychology,Georg-August-University Göttingen,Wilhelmsplatz 1,37073,Göttingen,Germany;[3]Department of Rheumatology and Immunology,Hannover Medical School,Carl-Neuberg-Straße 1,30625,Hannover,Germany;[4]German Centre for Infection Research(DZIF),Partner Site Hannover-Braunschweig,Carl-Neuberg-Straße 1,30625,Hannover,Germany;[5]Division of Molecular Immunology,Department of Internal Medicine 3,Friedrich-Alexander University of Erlangen-Nürnberg,Glückstraße 6,91054,Erlangen,Germany;[6]Centre for Individualized Infection Medicine(CiiM),Feodor-Lynen-Straße 7,30625,Hannover,Germany 出　　处：《Cellular & Molecular Immunology》索引2023年第20卷第8期,共3页 基　　金：SP acknowledges funding by the EU project UNDINE(grant agreement number 101057100);the Ministry for Science and Culture of Lower Saxony(Niedersächsisches Ministerium für Wissenschaft und Kultur,14-76103-184,COFONI Network,including projects 7FF22,6FF22,10FF22);the German Research Foundation(Deutsche Forschungsgemeinschaft,DFG,PO 716/11-1);H-MJ received funding from BMBF(01KI2043,NaFoUniMedCovid19-COVIM:01KX2021);Bavarian State Ministry for Science and the Arts(Bayerisches Staatsministerium für Wissenschaft und Kunst)and DFG through the research training groups RTG1660 and TRR130,the Bayerische Forschungsstiftung(Project CORAd)and the Kastner Foundation.GMNB acknowledges funding by the German Centre for Infection Research(Deutsches Zentrum für Infektionsforschung,DZIF;grant no 80018019238);Further,GMNB and AD-J acknowledge funding by a European Regional Development Fund(Defeat Corona,ZW7-8515131). 摘　　要：Despite previous circulation of the highly transmissible and antibody evasive BA.2.75, BQ.1, XBB.1 and XBB.1.5 lineages, the share of infections caused by the SARS-CoV-2 lineage XBB.1.16 has gradually increased in India in early 2023, resulting in XBB.1.16 being the dominating SARS-CoV-2 lineage in India today. Since a similar trend may also take place in other countries and information on the biological properties of the XBB.1.16 lineage is scarce, we conducted a rapid assessment of the SARS-CoV-2 XBB.1.16 lineage with respect to its ability to enter cells and evade neutralisation by antibodies. 关 键 词：LINEAGE NEUTRAL SPITE